Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+Early Breast Cancer in the United States

Sussell, J; Jhuti, GS; Antao, V; Herrera-Restrepo, O; Wehler, E; Bilir, SP

Sussell, J (corresponding author), 1 DNA Way,Bldg 35, San Francisco, CA 94080 USA.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021; 44 (7): 340

Abstract

Objective: Ado-trastuzumab emtansine (T-DM1) was recently approved for patients with human epidermal growth factor receptor 2 positive (HER2+) early b......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索